Drugs / iNeo-Vac-R01
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06019702 | Sep 2023 → Aug 2027 expected | digestive system neoplasm | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06026800 | Sep 2023 → Aug 2027 expected | digestive system neoplasm | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06026774 | Sep 2023 → Aug 2027 expected | digestive system neoplasm | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07495215 | Sep 2025 → Dec 2028 expected | hepatocellular carcinoma | Yinghua Xu | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07368803 | Sep 2025 → Sep 2027 expected | biliary tract cancer | Yifan Wang | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06995105 | Apr 2025 → Apr 2027 expected | hepatocellular carcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06956716 | Apr 2025 → Apr 2027 expected | intrahepatic cholangiocarcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06888674 | Apr 2025 → Apr 2027 expected | pancreas disorder | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06888648 | Apr 2025 → Apr 2027 expected | malignant pancreatic neoplasm | Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNeo-Vac-R01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06888674 ↗ |
| Modality | Messenger RNA (mRNA) | “Personalized mRNA vaccine encoding neoantigen, IH injection” NCT06019702 ↗ |
| Route | Other | “IH injection” NCT06026800 ↗ |